title: Lipid-rich carcinoma of the breast clinicopathologic analysis of 17 cases.
abstract: Lipid-rich carcinoma of the breast is a rare variant of breast cancer, accounted for <1% of all breast malignant tumors. We retrospectively analyzed the clinicopathologic characteristics of lipid-rich carcinomas of the breast. A panel of estrogen receptor, progesterone receptor, human epidermal growth factor receptor-2 (HER-2), cytokeratin (CK) 5/6, CK14, and P63 was prepared for detection of lipid-rich carcinoma. Fluorescence in situ hybridization and electron microscope assays were performed for detecting HER-2 gene amplification and ultrastructure. Survival analysis were carried out using Kaplan-Meier and Cox regression methods. Receiver operating characteristic test was also performed. Estrogen receptor, CK5/6, CK14, and P63 were negative. Progesterone receptor (1/17) and HER-2 (17/17) were positive. HER-2 gene amplification was detected in all included cases (ratio values >2.2). Ultrastructure showed fat droplet and electron-dense material in the cytoplasm. Statistical differences were detected among survival and age (P = .033), histologic grade (P = .004), lymph node involvement (P = .001), and HER-2 expression (P = .002), respectively, using Kaplan-Meier methods. Statistical differences were also detected (P = .017) using Cox regression methods. Receiver operating characteristic test displayed significant statistical differences; the prognosis had a correlation between HER-2 expression "+" and HER-2 expression "++" (P = .004). Lipid-rich carcinoma of the breast was an HER-2 overexpressing subtype of the breast carcinoma. Survival of lipid-rich carcinoma might be associated with age, histologic grade, lymph node involvement, and HER-2. The HER-2 expression, however, might play an important role in predicting the prognosis of lipid-rich carcinoma of the breast.
authors.affiliation: Department of Pathology, School of Medicine Nanjing University/Nanjing Jinling Hospital, Nanjing, P.R. China.
authors.forename: Bing
authors.initials: B
authors.lastname: Guan
authors.forename: Hai
authors.initials: H
authors.lastname: Wang
authors.forename: Shougen
authors.initials: S
authors.lastname: Cao
authors.forename: Qiu
authors.initials: Q
authors.lastname: Rao
authors.forename: Yan
authors.initials: Y
authors.lastname: Wang
authors.forename: Yun
authors.initials: Y
authors.lastname: Zhu
authors.forename: Qunli
authors.initials: Q
authors.lastname: Shi
authors.forename: Honglin
authors.initials: H
authors.lastname: Yin
authors.forename: Xuan
authors.initials: X
authors.lastname: Wang
authors.forename: Xiaojun
authors.initials: X
authors.lastname: Zhou
mesh_terms: D000230:Adenocarcinoma / Q000737:chemistry / Q000235:genetics / Q000401:mortality / Q000556:secondary*; D000328:Adult; D000368:Aged; D014408:Biomarkers, Tumor / Q000032:analysis / Q000235:genetics; D001943:Breast Neoplasms / Q000737:chemistry / Q000235:genetics / Q000401:mortality / Q000473:pathology*; D003593:Cytoplasm / Q000737:chemistry / Q000648:ultrastructure; D004273:DNA, Neoplasm / Q000032:analysis; D005260:Female; D005784:Gene Amplification; D018734:Genes, erbB-2 / Q000235:genetics; D006801:Humans; D007150:Immunohistochemistry; D017404:In Situ Hybridization, Fluorescence; D053208:Kaplan-Meier Estimate; D008055:Lipids / Q000032:analysis*; D008875:Middle Aged; D009367:Neoplasm Staging; D017698:Postmenopause; D011379:Prognosis; D012372:ROC Curve; D012189:Retrospective Studies; D015996:Survival Rate
chemical_list: D014408:Biomarkers, Tumor; D004273:DNA, Neoplasm; D008055:Lipids